Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

19.69USD
16 Feb 2018
Change (% chg)

$-0.41 (-2.04%)
Prev Close
$20.10
Open
$20.00
Day's High
$20.19
Day's Low
$19.04
Volume
19,685
Avg. Vol
47,828
52-wk High
$28.56
52-wk Low
$12.04

Chart for

About

G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.... (more)

Overall

Beta: --
Market Cap(Mil.): $558.12
Shares Outstanding(Mil.): 28.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Medimmune Ventures Sells 133,906 Shares Of G1 Therapeutics Inc's Common Stock On Dec 1

* MEDIMMUNE VENTURES INC REPORTS SALE OF 133,906 SHARES OF G1 THERAPEUTICS INC'S COMMON STOCK ON DEC 1 AT $19.75 PER SHARE - SEC FILING Source text: (http://bit.ly/2iVgOvs) Further company coverage:

Dec 05 2017

BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer

* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER

Nov 28 2017

BRIEF-G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​

* G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​

Nov 08 2017

BRIEF-G1 Therapeutics qtrly ‍loss per share $0.55

* G1 therapeutics reports third quarter 2017 financial results and recent operational highlights

Nov 08 2017

Earnings vs. Estimates